Meeting
2023 ASCO Annual Meeting
First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.
Authors
Adil Daud
University of California-San Francisco, San Francisco, CA
Adil Daud , Costantine Albany , Vamsidhar Velcheti , Ralph J. Hauke , Jordi Rodon Ahnert , Daniel D. Karp , Apostolia Maria Tsimberidou , Julia Wanda Cohen , Emmett V. Schmidt , Jieyi Wang , C. Hubert Chan , Siqing Fu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT04130542
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2525)
DOI
10.1200/JCO.2023.41.16_suppl.2525
Abstract #
2525
Poster Bd #
367
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
First Author: Lisa Zimmer
Poster
2017 ASCO Annual Meeting
Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+ advanced, relapsed, or refractory solid tumor or lymphoma.
First Author: Birgit Geoerger
Poster
2023 ASCO Annual Meeting
Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.
First Author: Yiqun Du
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
First Author: Jermaine Coward